We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Sovaldi

News List

Brazilian court strips Gilead of its patent for Hepatitis C drug Sovaldi pharmaceutical-technology
September 30, 2018
A judge from the 21st Federalist Court of Brasilia has ruled to invalidate US biopharma company Gilead’s exclusivity patent for Sovaldi (sofosbuvir), which is indicated for Hepatitis C.
Gilead to launch authorised generic versions of hepatitis C drugs Epclusa, Harvoni next year in US firstwordpharma
September 25, 2018
Gilead Sciences announced Monday that it plans to launch authorised generic versions of its hepatitis C therapies Epclusa (sofosbuvir/velpatasvir) and Harvoni (ledipasvir/sofosbuvir) in the US next year.
Gilead lowers the price to launche hep C drug Sovaldi in China pharmafile
November 30, 2017
Gilead has officially launched its hepatitis C drug Sovaldi (sofosbuvir) in the Chinese market, but with one major caveat: it will cost 58,980 yuan in the region, just one-fifth of its price tag in the US – a price which has fallen rapidly from the $84,0
FDA approves new indications for Harvoni and Sovaldi cphi-online
April 11, 2017
First HCV direct-acting antivirals approved for use in adolescents.